always immediately lethal but are worth treating with radiotherapy and patients may survive many years after treatment; 12 new cases and 11 recurrences were seen in this series. Dysgerminomas were less commononly 8 new cases being seen in the same period; they were younger but survival was quite good and showed that it may be a matter of years even after several recurrences.
A study of results related to duration of symptoms shows that, as with malignant disease in other sites, early diagnosis does not necessarily lead to improved cure rate. The five-year survival rate in patients with symptoms going back less than two months was 27% and even in the 3-8 months group, 22 %; when the delay was more than nine months, it was 24 %. In the first group in spite of the short history there was a large proportion of Stage III and IV cases, while in the group with a long history there was a surprising number of patients with early disease. The malignancy of the tumour is more important than the speed of the diagnosis.
As in other series the results became worse with increasing age. Table 5 gives the results of all stages and histological groups of the cystadenocarcinoma.
Although the results of the whole group are poor-24 % five-year survivalcertain types are not unfavourable. Patients with a well-differentiated tumour which has not penetrated the capsule show an 86 % five-year survival rate but such cases are rare. The main points of interest are the poor results with less well-differentiated tumours, even in the early stages, and the almost complete hopelessness of the prognosis once disease has spread outside the pelvis.
Professor Dr H G Limburg (Universitdtskliniken imLandeskrankenhaus, Homburg, Saar, Germany)
Chemotherapy in the Treatment of Ovarian Cancer
The varying reactions of human tumours of the female genitalia, especially of ovarian cancers, to modern cytostatic drugs were examined with the aid of primary tissue cultures in vitro. The cultivations are performed in a Leighton tube by means of the trypsinizing method (Dulbecco & Vogt 1954) . The total material evaluated to date includes more than 1,400 explanted human tissues, the success rate being 80%; in ovarian cancers 94%.
The primary cultures include normal squamous epithelium of the cervix, carcinoma-in-situ, cancer of the cervix and corpus, ovarian cancer and ovarian carcinoma ascites. With the aid of these tissue cultures examinations were carried out to observe the varying reactions of tumour cells to cytostatic drugs such as cyclophosphamide mitomen, methotrexate, methylhydrazin, SPI 77, thiothepa, triaziquone and vinblastine. Adapting the dosage of the chemotherapeutic substances in vitro to the actual conditions of the clinical treatment it has been possible in 300 cases to judge the probable efficacy of the substance. This 'cancer chemotherapy sensitivity test' shows completely different individual reactions from the completely resistant culture to the cytolytic destruction of the cell monolayer, although the tumour morphology may be equal or similar. By the test, one is in a position to apply an individually determined cytostatic therapy to every kind of tumour provided that at least one of the drugs is effective. The clinical results of selective chemotherapy of cancer of the female genitalia are demonstrated by the survival rates and clinical criteria of those treated as compared to those without selective chemotherapy. An accurate objective response index based on gross tumour regression is possible in patients previously receiving the TNM classification before definitive treatment. The T classification which is based as a rule on simple clinical examination is inappropriate. Accordingly TP, which takes into account the findings at operation, should be used following the recommendations of the International Union Against Cancer (UICC), Geneva 1966 (Kottmeier 1968 ).
In the patients under investigation the implantation of tumour masses or metastases were present within the peritoneal cavity including the omentum, small intestine, mesentery, liver or other viscera (Mlb) and in several cases outside the peritoneal cavity (Mlc). Any major effect of chemotherapy on survival should be discernible, unless the histological classification of the epithelial tumours of the ovary is provided after the proposal of the Cancer Committee of the International Federation of Gynecology and Obstetrics, August 1961. A longer survival of Stage IV patients could reflect an originally slower growing neoplasm, a low potential malignancy of a highly differentiated type in the histological specimen.
Therefore, serous and mucinous cysts of ovarian cancer as well as endometrioid malignant tumours of the ovary have been eliminated from the patients under study. The remaining collective consists of undifferentiated carcinoma of the ovaries. The homogeny of the clinical stage of the disease and of the growth characteristics of the tumour provides a comparative appraisal of chemotherapy for ovarian cancer. Table 1 demonstrates the medium survival rate in days of a selective chemotherapy after the sensitivity test was performed in 25 patients contrasted with 14 without chemotherapy and 15 with conventional chemotherapy without the sensitivity test. The preponderance of advanced disease in this series was evident since there were 10 cases with tumour masses outside the peritoneal cavity, compared to 2 cases without test and 4 cases treated with no cancerostatic agent. The data shown reveal a rise of mean survival time by application of cytostatic drugs from 82 to 283 days corresponding to 71 %. The average duration of life span rose from 283 to 527 days in the course of selective chemotherapy after the sensitivity test was employed. Out of 25 patients treated, 7 achieved excellent remissions consisting of total regression of all palpable masses, pleural effusions and ascites associated with a return to a normal living routine.
The t test (Student distribution) of survival rates revealed a statistical significance of P less than 0 01 and 0 001 respectively. Fig 1 correlates the survival time in the three therapy groups between patients who died and survivors expecting further prolongation of their life span. Thus the one-year survival is 33 % without and 64% after sensitivity testing. The twoyear survival still approximates in both groups at 20 % but still gains significant difference with the prolongation of the observation time. After three years only 12% in the tested group with selective chemotherapy are alive.
In conclusion, one may say the extremely low percentage of one-year survivors in Stage IV cases as confirmed in other series with palliative operation and radiotherapy can be overcome by the selective chemotherapy. The cancer chemotherapy sensitivity test is a valuable tool in selecting the most effective cytostatic drug. The resistance of the malignant tumour to the carcinostatic agent is no longer a therapeutic problem when the sensitivity test is performed.
